Fig. 3
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-016-2254-9/MediaObjects/12885_2016_2254_Fig3_HTML.gif)
SFK inhibitors affect phosphorylation in non-metastatic ccRCC cell lines. a Western blots showing the effect of control (C), 10 % Serum (V), 1, 10, 50 or 100 nM dasatinib or saracatinib on SFK (Y416), FAK (Y861) and Src kinase in the non-metastatic, 769-P and 786-O and metastatic ACHN cells. b–d Quantification of western blot results for dasatinib (black bars) and saracatinib (grey bars) in (b) 769-P, (c) 786-O and (d) ACHN cells (n = 3-4: * = 0.05, ** = 0.01, *** = 0.001)